Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.

Abstract

AIMS Glimepiride is a new sulfonylurea for diabetes treatment which is supposed to impact less on extra-pancreatic ATP-dependent K+ channels than the conventional drug glibenclamide. This study was performed to evaluate whether this results in a better maintenance of ATP-dependent K+ channel mediated ischaemic myocardial preconditioning. METHODS AND… (More)

Topics

Cite this paper

@article{Klepzig1999SulfonylureasAI, title={Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.}, author={Heiner Klepzig and George M. Kober and Cheryl Matter and Herman Gerhardus Luus and H. Schneider and Katja Boedeker and Wolfgang Kiowski and F. W. Amann and Dorota Gruber and S. Harris and W. Burger}, journal={European heart journal}, year={1999}, volume={20 6}, pages={439-46} }